Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ARDT vs UHS vs HCA vs THC vs CYH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
ARDT vs UHS vs HCA vs THC vs CYH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $1.45B | $10.64B | $97.29B | $16.68B | $393M |
| Revenue (TTM) | $6.43B | $17.76B | $75.60B | $21.45B | $21.48B |
| Net Income (TTM) | $134M | $1.52B | $6.78B | $1.70B | $-88M |
| Gross Margin | 60.5% | 67.6% | 41.5% | 42.8% | 53.7% |
| Operating Margin | 8.9% | 11.5% | 15.8% | 16.1% | -39.8% |
| Forward P/E | 9.0x | 7.3x | 14.4x | 10.7x | 0.7x |
| Total Debt | $2.26B | $5.51B | $50.20B | $13.17B | $11.58B |
| Cash & Equiv. | $710M | $138M | $1.04B | $2.88B | $260M |
ARDT vs UHS vs HCA vs THC vs CYH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Ardent Health Partn… (ARDT) | 100 | 56.6 | -43.4% |
| Universal Health Se… (UHS) | 100 | 79.5 | -20.5% |
| HCA Healthcare, Inc. (HCA) | 100 | 119.9 | +19.9% |
| Tenet Healthcare Co… (THC) | 100 | 127.2 | +27.2% |
| Community Health Sy… (CYH) | 100 | 53.0 | -47.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARDT vs UHS vs HCA vs THC vs CYH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, ARDT doesn't own a clear edge in any measured category.
UHS is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 9.7%, EPS growth 37.3%, 3Y rev CAGR 9.0%
- Lower volatility, beta 0.62, Low D/E 74.3%, current ratio 1.05x
- 9.7% revenue growth vs CYH's -1.2%
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.31, yield 0.7%
- Beta 0.31, yield 0.7%, current ratio 0.83x
- 9.0% margin vs CYH's -0.4%
- Beta 0.31 vs CYH's 1.57
THC ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 5.1% 10Y total return vs HCA's 457.9%
- PEG 0.32 vs HCA's 0.68
- +27.7% vs ARDT's -30.6%
CYH is the clearest fit if your priority is value.
- Lower P/E (0.7x vs 14.4x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.7% revenue growth vs CYH's -1.2% | |
| Value | Lower P/E (0.7x vs 14.4x) | |
| Quality / Margins | 9.0% margin vs CYH's -0.4% | |
| Stability / Safety | Beta 0.31 vs CYH's 1.57 | |
| Dividends | 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.7% vs ARDT's -30.6% | |
| Efficiency (ROA) | 11.3% ROA vs CYH's -0.7%, ROIC 19.9% vs -70.1% |
ARDT vs UHS vs HCA vs THC vs CYH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ARDT vs UHS vs HCA vs THC vs CYH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCA leads in 3 of 6 categories
THC leads 2 • CYH leads 1 • ARDT leads 0 • UHS leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 11.8x ARDT's $6.4B. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to CYH's -0.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $6.4B | $17.8B | $75.6B | $21.5B | $21.5B |
| EBITDAEarnings before interest/tax | $733M | $2.7B | $15.5B | $4.3B | -$7.8B |
| Net IncomeAfter-tax profit | $134M | $1.5B | $6.8B | $1.7B | -$88M |
| Free Cash FlowCash after capex | $214M | $894M | $7.7B | $3.3B | -$200M |
| Gross MarginGross profit ÷ Revenue | +60.5% | +67.6% | +41.5% | +42.8% | +53.7% |
| Operating MarginEBIT ÷ Revenue | +8.9% | +11.5% | +15.8% | +16.1% | -39.8% |
| Net MarginNet income ÷ Revenue | +2.1% | +8.6% | +9.0% | +7.9% | -0.4% |
| FCF MarginFCF ÷ Revenue | +3.3% | +5.0% | +10.2% | +15.6% | -0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.0% | +9.6% | +6.7% | +2.8% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +17.7% | +44.6% | +87.6% | -45.2% |
Valuation Metrics
CYH leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 0.7x trailing earnings, CYH trades at a 95% valuation discount to HCA's 15.3x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.37x vs HCA's 0.73x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.4B | $10.6B | $97.3B | $16.7B | $393M |
| Enterprise ValueMkt cap + debt − cash | $3.0B | $16.0B | $146.5B | $27.0B | $11.7B |
| Trailing P/EPrice ÷ TTM EPS | 10.53x | 7.36x | 15.33x | 12.29x | 0.74x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.99x | 7.27x | 14.40x | 10.65x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 0.46x | 0.73x | 0.37x | — |
| EV / EBITDAEnterprise value multiple | 6.24x | 6.13x | 9.46x | 6.27x | — |
| Price / SalesMarket cap ÷ Revenue | 0.23x | 0.61x | 1.29x | 0.78x | 0.03x |
| Price / BookPrice ÷ Book value/share | 0.85x | 1.48x | — | 1.93x | — |
| Price / FCFMarket cap ÷ FCF | 5.59x | 12.53x | 12.65x | 6.59x | 1.89x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $8 for ARDT. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs CYH's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.0% | +20.7% | — | +19.6% | — |
| ROA (TTM)Return on assets | +2.6% | +9.8% | +11.3% | +5.7% | -0.7% |
| ROICReturn on invested capital | +7.5% | +12.3% | +19.9% | +13.2% | -70.1% |
| ROCEReturn on capital employed | +7.9% | +16.0% | +27.0% | +13.8% | -87.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 7 | 7 | 6 |
| Debt / EquityFinancial leverage | 1.34x | 0.74x | — | 1.47x | — |
| Net DebtTotal debt minus cash | $1.6B | $5.4B | $49.2B | $10.3B | $11.3B |
| Cash & Equiv.Liquid assets | $710M | $138M | $1.0B | $2.9B | $260M |
| Total DebtShort + long-term debt | $2.3B | $5.5B | $50.2B | $13.2B | $11.6B |
| Interest CoverageEBIT ÷ Interest expense | 6.36x | 10.92x | 5.37x | 4.28x | 4.89x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,325 today (with dividends reinvested), compared to $1,916 for CYH. Over the past 12 months, THC leads with a +27.7% total return vs ARDT's -30.6%. The 3-year compound annual growth rate (CAGR) favors THC at 39.8% vs ARDT's -14.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +17.0% | -22.6% | -7.3% | -4.5% | -10.0% |
| 1-Year ReturnPast 12 months | -30.6% | -7.1% | +23.8% | +27.7% | -17.7% |
| 3-Year ReturnCumulative with dividends | -37.0% | +20.4% | +59.6% | +173.1% | -19.8% |
| 5-Year ReturnCumulative with dividends | -37.0% | +10.8% | +111.2% | +193.3% | -80.8% |
| 10-Year ReturnCumulative with dividends | -37.0% | +30.3% | +457.9% | +511.4% | -81.0% |
| CAGR (3Y)Annualised 3-year return | -14.3% | +6.4% | +16.9% | +39.8% | -7.1% |
Risk & Volatility
HCA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than CYH's 1.57 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HCA currently trades 78.2% from its 52-week high vs CYH's 62.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.28x | 0.62x | 0.31x | 0.74x | 1.57x |
| 52-Week HighHighest price in past year | $15.48 | $246.33 | $556.52 | $247.21 | $4.47 |
| 52-Week LowLowest price in past year | $8.07 | $152.33 | $330.00 | $146.60 | $2.38 |
| % of 52W HighCurrent price vs 52-week peak | +65.3% | +69.0% | +78.2% | +77.0% | +62.4% |
| RSI (14)Momentum oscillator 0–100 | 54.3 | 42.6 | 30.7 | 52.6 | 47.7 |
| Avg Volume (50D)Average daily shares traded | 374K | 777K | 1.0M | 1.2M | 1.6M |
Analyst Outlook
HCA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ARDT as "Buy", UHS as "Hold", HCA as "Buy", THC as "Buy", CYH as "Hold". Consensus price targets imply 36.3% upside for THC (target: $260) vs 5.0% for CYH (target: $3). For income investors, HCA offers the higher dividend yield at 0.68% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $13.33 | $226.00 | $527.45 | $259.50 | $2.93 |
| # AnalystsCovering analysts | 12 | 43 | 46 | 32 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | +0.5% | +0.7% | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 | 5 | 0 | 2 |
| Dividend / ShareAnnual DPS | — | $0.80 | $2.94 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +9.1% | +10.3% | +8.6% | +0.5% |
HCA leads in 3 of 6 categories (Profitability & Efficiency, Risk & Volatility). THC leads in 2 (Income & Cash Flow, Total Returns).
ARDT vs UHS vs HCA vs THC vs CYH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ARDT or UHS or HCA or THC or CYH a better buy right now?
For growth investors, Universal Health Services, Inc.
(UHS) is the stronger pick with 9. 7% revenue growth year-over-year, versus -1. 2% for Community Health Systems, Inc. (CYH). Community Health Systems, Inc. (CYH) offers the better valuation at 0. 7x trailing P/E, making it the more compelling value choice. Analysts rate Ardent Health Partners, LLC (ARDT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARDT or UHS or HCA or THC or CYH?
On trailing P/E, Community Health Systems, Inc.
(CYH) is the cheapest at 0. 7x versus HCA Healthcare, Inc. at 15. 3x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 32x versus HCA Healthcare, Inc. 's 0. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ARDT or UHS or HCA or THC or CYH?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +193.
3%, compared to -80. 8% for Community Health Systems, Inc. (CYH). Over 10 years, the gap is even starker: THC returned +511. 4% versus CYH's -81. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARDT or UHS or HCA or THC or CYH?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 31β versus Community Health Systems, Inc. 's 1. 57β — meaning CYH is approximately 409% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — ARDT or UHS or HCA or THC or CYH?
By revenue growth (latest reported year), Universal Health Services, Inc.
(UHS) is pulling ahead at 9. 7% versus -1. 2% for Community Health Systems, Inc. (CYH). On earnings-per-share growth, the picture is similar: Community Health Systems, Inc. grew EPS 196. 7% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, UHS leads at 9. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ARDT or UHS or HCA or THC or CYH?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 2. 1% for Ardent Health Partners, LLC — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -79. 4% for CYH. At the gross margin level — before operating expenses — ARDT leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ARDT or UHS or HCA or THC or CYH more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 32x versus HCA Healthcare, Inc. 's 0. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 14. 4x for HCA Healthcare, Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 36. 3% to $259. 50.
08Which pays a better dividend — ARDT or UHS or HCA or THC or CYH?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield) pay a dividend. ARDT, THC, CYH do not pay a meaningful dividend and should not be held primarily for income.
09Is ARDT or UHS or HCA or THC or CYH better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31), 0. 7% yield, +457. 9% 10Y return). Community Health Systems, Inc. (CYH) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +457. 9%, CYH: -81. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ARDT and UHS and HCA and THC and CYH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
HCA pays a dividend while ARDT, UHS, THC, CYH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.